Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan by Hattori, Nobutaka et al.
TitleRasagiline monotherapy in early Parkinson's disease: A phase3, randomized study in Japan
Author(s)
Hattori, Nobutaka; Takeda, Atsushi; Takeda, Shinichi;
Nishimura, Akira; Kitagawa, Tadayuki; Mochizuki, Hideki;
Nagai, Masahiro; Takahashi, Ryosuke




© 2018 The Authors. Published by Elsevier Ltd. This is an





Contents lists available at ScienceDirect
Parkinsonism and Related Disorders
journal homepage: www.elsevier.com/locate/parkreldis
Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized
study in Japan
Nobutaka Hattoria,∗, Atsushi Takedab, Shinichi Takedac, Akira Nishimurac, Tadayuki Kitagawac,
Hideki Mochizukid, Masahiro Nagaie, Ryosuke Takahashif
a Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan
bDepartment of Neurology, National Hospital Organization Sendai Nishitaga Hospital, Miyagi, Japan
c Japan Development Center, Takeda Pharmaceutical Company Limited, Osaka, Japan
d Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
e Clinical Therapeutic Trial Center, Ehime University Hospital, Ehime, Japan
fDepartment of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan







A B S T R A C T
Background: Rasagiline is a monoamine oxidase type-B inhibitor in development in Japan for Parkinson's disease
(PD). The objective of this Phase 3, randomized, double-blind study was to evaluate the efficacy and safety of
rasagiline in Japanese patients with early PD (NCT02337725).
Methods: Patients were 30–79 years old with a diagnosis of PD within 5 years. Following a two-week placebo
run-in period, patients were randomized 1:1 to receive rasagiline (1 mg/day) or placebo for up to 26 weeks. The
primary endpoint was change from baseline in the MDS-UPDRS Part II + III total score (TS). Secondary end-
points included the MDS-UPDRS Parts II + III, III, II, and I TS and safety.
Results: In total, 118 patients were randomized to rasagiline and 126 to placebo. Patient characteristics at
baseline were similar in both groups. The change from baseline in the MDS-UPDRS Part II + III TS was sig-
nificantly greater in the rasagiline vs. placebo group (rasagiline-placebo: −6.39, 95% CI: −8.530, −4.250;
P < 0.0001). The mean changes from baseline in the MDS-UPDRS Part II + III, Part III and Part II TS were
lower at treatment visits between weeks 6 and 26 in the rasagiline vs. placebo groups. The overall incidence of
treatment-emergent adverse events (TEAEs) was 62.4% and 52.4% in the rasagiline and placebo groups, re-
spectively; most frequent TEAE was nasopharyngitis (15.4% and 15.1%).
Conclusion: Treatment with oral rasagiline 1 mg/day was effective and well-tolerated in Japanese patients with
early PD, with a significantly greater improvement in the MDS-UPDRS Part II + III TS vs. placebo, and a similar
safety profile.
1. Introduction
Parkinson's disease (PD) is the second most common neurodegen-
erative disorder after Alzheimer's disease [1,2], affecting more than 1%
of people aged older than 60 years old, and up to 4% of those aged more
than 80 years old, worldwide [3]. In Japan, the overall prevalence is
estimated to be between 100 and 150 per 100,000 people [4].
Loss of dopaminergic neurons and resulting deficiency in dopami-
nergic neurotransmission in the nigrostriatal pathway underlies the
classical parkinsonian motor symptoms: bradykinesia, resting tremor,
muscle rigidity, and postural instability [1,4]. There is no cure for PD,
but current treatment options to alleviate symptoms include levodopa,
dopamine agonists, and monoamine oxidase B inhibitors (MAOB-Is)
[1,3–5]. MAOB-Is act by inhibiting the breakdown of dopamine by
monoamine oxidase, thereby increasing the amount of dopamine in the
striatum [6]. Levodopa is a precursor of dopamine and is the most ef-
fective and commonly used drug for the symptomatic treatment of PD,
but long-term use is associated with motor complications [1,3–5,7].
Consequently, MAOB-Is have been recommended as first-line treatment
for mild PD in Western countries [3,5]. In Japan, treatment and man-
agement guidelines for PD published by the Japanese Society of Neu-
rology in 2011, recommend that treatment of symptoms should begin
with levodopa or a dopamine agonist [8], because monotherapy using
selegiline (the only MAOB-I available in Japan when the guidelines
were published) was not approved until 2015 [9].
Rasagiline is a selective and irreversible MAOB-I [7], which has
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been evaluated in four key Phase 3 clinical trials, in North America and
Europe [10–13]. In the TEMPO study, patients with early PD who re-
ceived 1mg/day rasagiline monotherapy for 26 weeks had a 4.2-point
reduction in Unified Parkinson's Disease Rating Scale (UPDRS) total
score, greater than the reduction that occurred with placebo [11]. In
the ADAGIO study, between weeks 12 and 36 of treatment, an increase
in UPDRS score occurred in the placebo group, with a smaller increase
in the rasagiline 1mg/day group; early-treatment with 1mg/day (but
not 2mg/day) rasagiline was superior to delayed-start treatment [10].
Quality of life measured using the Parkinson's Disease Quality of Life
questionnaire (PDQUALIF) was shown to be improved after 26 weeks of
rasagiline therapy [14]. The efficacy and safety of rasagiline as an ad-
junct to levodopa have also been demonstrated in patients with more
advanced disease [12,13]. As of June 2017, rasagiline is approved in 55
countries, including the USA and several European countries, for
treatment of PD as monotherapy or combination therapy with levodopa
or a dopamine agonist [15].
To date, no controlled studies have evaluated rasagiline mono-
therapy for Japanese patients with early PD. We conducted a study to
evaluate the efficacy and safety of 26 weeks of oral rasagiline (1mg/
day) as monotherapy in Japanese patients with early PD, using changes
in the Movement Disorder Society-Unified Parkinson's Disease Rating
Scale scores [16,17] (MDS-UPDRS) as efficacy endpoints.
2. Methods
2.1. Study design
This was a multicenter, randomized, double-blind, placebo-con-
trolled, parallel-group, Phase 3 study (NCT02337725) to evaluate the
efficacy and safety of rasagiline in Japanese patients with early PD. The
study consisted of an initial two-week single-blind run-in period, in
which patients received placebo once daily for 2 weeks, followed by a
26-week double-blind treatment period, in which patients were ran-
domized 1:1 to receive either placebo or oral rasagiline 1mg/day
(Supplementary Fig. 1).
The run-in period was designed to reduce the influence of placebo
response on the study results.
The study was reviewed and approved by the Institutional Review
Board (IRB) at each of the participating study centers.
2.2. Patients
Eligible patients were aged 30–79; had been diagnosed with PD in
the previous 5 years; had at least two of the following symptoms:
resting tremor, akinesia/bradykinesia, muscle rigidity; had a MDS-
UPDRS Part II + Part III total score≥14, and a modified Hoehn & Yahr
[18] stage score of 1–3 at the start of the run-in period (visit 1). For
enrollment into the treatment period, patients were required to have a
MDS-UPDRS Part II + Part III total score of ≥14 at baseline (week 0).
Key exclusion criteria included: use of any investigational drug
within 90 days prior to visit 1; previous use of rasagiline; a Mini-Mental
State Examination (MMSE) score ≤24; treatment with amantadine or
an anticholinergic drug for ≥180 days; treatment with selegiline, le-
vodopa or dopamine agonists for≥90 days; use of selegiline within 90
days of visit 1, or of any medication containing levodopa, dopamine
agonists, amantadine or anticholinergic drugs within 30 days of visit 1.
Concomitant use of antidepressants was prohibited.
This study was conducted in accordance with the ethical principles
that have their origin in the Declaration of Helsinki, as well as Good
Clinical Practice, and all applicable laws and regulations. All patients
provided written, informed consent.
2.3. Endpoints and assessments
The primary endpoint was the change in MDS-UPDRS Part II (motor
aspects of activities of daily living) + Part III (motor examination) total
score from baseline (week 0) to week 26 (Last Observation Carried
Forward [LOCF]) of the treatment period. The secondary endpoints
were changes from baseline to each visit throughout the treatment
period in: MDS-UPDRS Part II + Part III total score; MDS-UPDRS Part I
(non-motor aspects of experiences of daily living) total score; MDS-
UPDRS Part II total score; and MDS-UPDRS Part III total score.
Additional endpoints were proportion of patients with a change from
baseline to week 26 in the MDS-UPDRS Part II + Part III total
score< 3, changes from baseline to week 26 (LOCF) in MDS-UPDRS
tremor, bradykinesia, and muscle rigidity scores, and in the Parkinson's
Disease Questionnaire-39 (PDQ-39) [19] summary index and scores for
individual domains of the PDQ-39. Safety was assessed by evaluating
the incidence of treatment-emergent adverse events (TEAEs), classified
using the Medical Dictionary for Regulatory Activities (MedDRA) ver-
sion 19.0.
The MDS-UPDRS evaluation was performed by accredited in-
vestigators (except Part IB and Part II, which were self-evaluated by
patients). Scores were recorded at every visit, except week 3. The PDQ-
39 questionnaire was self-administered and scores were recorded at
weeks 0, 14 and 26.
2.4. Statistical analysis
An analysis of covariance (ANCOVA) model was used to evaluate
the least square (LS) mean change in the MDS-UPDRS scores from
baseline to week 26 for the primary endpoint, and from baseline to each
visit of the treatment period for the secondary endpoints, with baseline
values as covariates. Logistic regression was performed to evaluate the
odds ratio for a change from baseline to week 26 in the MDS-UPDRS
Part II + Part III total score being<3. Changes in PDQ-39 scores from
baseline to week 26 were also analyzed by ANCOVA. Missing data were
accounted for by the LOCF method.
For sample size calculation, a two-sample t-test with a two-sided 5%
significance was applied. Assuming the effect size for the mean differ-
ence in the change from baseline to week 26 in MDS-UPDRS Part
II + Part III total scores between the rasagiline and placebo groups to
be −0.44, a sample size of 240 patients (120 per group) was found to




The study was conducted at 68 sites in Japan, between February
2015 and September 2016. Of the 267 screened patients, 253 were
enrolled into the run-in period. Of these, 244 were randomized to re-
ceive placebo (n=126) or rasagiline (n= 118); 100 patients in the
placebo group and 110 patients in the rasagiline group completed the
study (Supplementary Fig. 2). The main reason for discontinuation in
the placebo and rasagiline groups was voluntary withdrawal and ad-
verse events, respectively.
At baseline (week 0), patient characteristics were generally well
balanced between treatment groups (Table 1). The mean MDS-UPDRS
Part II + Part III total score was 33.8 in the placebo group and 34.4 in
the rasagiline group.
3.2. Efficacy
At week 26 (LOCF), the LS mean change from baseline in the MDS-
UPDRS Part II + Part III total score (primary endpoint) was 1.87 (95%
confidence interval [CI]: 0.385, 3.347) for the placebo group and
−4.52 (95% CI: −6.068 -2.980) for the rasagiline group (Table 2),
representing a relative improvement in symptoms for patients receiving
rasagiline vs. placebo. The difference between groups was statistically
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significant (rasagiline-placebo: −6.39, 95% CI: −8.530, −4.250;
P < 0.0001).
There was a greater decrease in the MDS-UPDRS Part II + Part III
and Part III total scores from baseline at treatment visits between weeks
6 and 26 (inclusive) in the rasagiline group compared with the placebo
group (Fig. 1A, B). Between weeks 6 and 26, the MDS-UPDRS Part II
score increased with placebo, but not with rasagiline, representing an
improvement in symptoms in the rasagiline group compared with pla-
cebo (Fig. 1C). For the MDS-UPDRS Part I total score, the mean change
from baseline was similar for both groups at week 6, but was less for the
rasagiline group than the placebo group between weeks 10 and 26
(Fig. 1D).
The LS mean change from baseline to week 26 (LOCF) in the MDS-
UPDRS Part III total score was −0.48 and −4.47 for the placebo and
rasagiline groups, respectively; the between-group difference was sta-
tistically significant (−3.98, 95% CI: −5.800, −2.165; P < 0.0001).
There was an increase in MDS-UPDRS Part II and Part I total scores from
baseline to week 26 (LOCF) in both treatment groups; it was greater in
the placebo group. The LS mean difference between groups was sta-
tistically significant for both Part II (−2.19, 95% CI:−3.143,−1.235,
P < 0.0001) and Part I total scores (−0.80, 95% CI:−1.504,−0.099,
P= 0.0255) (Table 2).
The proportions of patients with a change from baseline to week 26
in the MDS-UPDRS Part II + Part III total score of< 3 were 81.7% and
53.6% in the rasagiline and placebo groups, respectively; this difference
was statistically significant (odds ratio 3.93; 95% CI: 2.172, 7.123;
P < 0.0001). LS mean changes from baseline to week 26 (LOCF) with
placebo and rasagiline were 0.02 and −1.20, respectively, for MDS-
UPDRS tremor, −0.14 and −1.69 for MDS-UPDRS bradykinesia, and
−0.21 and −1.00 for MDS-UPDRS rigidity (Table 2). All the differ-
ences between treatment groups were statistically significant.
At week 26 (LOCF), the LS mean change from baseline in the PDQ-
39 summary index was 2.84 for the placebo group vs. 1.24 for the ra-
sagiline group; the difference between groups was not statistically
Table 1




Age, years, mean (SD) 65.4 (8.81) 67.4 (8.96)
≥65 years, n (%) 79 (62.7) 79 (66.9)
Female, n (%) 72 (57.1) 65 (55.1)
Duration of Parkinson's disease, years; mean (SD) 1.56 (1.24) 1.97 (1.97)
Modified Hoehn & Yahr stage, mean (SD) 2.15 (0.62) 2.18 (0.63)
MDS-UPDRS Part II + Part III total score, mean (SD)a 33.8 (14.43) 34.4 (16.95)
MDS-UPDRS Part I total score, mean (SD)a 5.7 (3.58) 5.5 (3.83)
MDS-UPDRS Part II total score, mean (SD)a 7.0 (4.64) 7.2 (5.47)
MDS-UPDRS Part III total score, mean (SD)a 26.8 (11.59) 27.2 (13.80)
MDS-UPDRS tremor score, mean (SD)a 5.8 (4.64) 5.7 (4.52)
MDS-UPDRS bradykinesia score, mean (SD)a 11.6 (5.92) 12.3 (7.06)
MDS-UPDRS rigidity score, mean (SD)a 6.2 (3.33) 5.9 (3.34)
PDQ-39 summary index, mean (SD)a 11.98 (11.52) 10.50 (10.04)
Levodopa use before the start of the study, n (%)b 16 (12.70) 15 (12.82)
Dopamine agonist before the start of the study, n (%)b 1 (0.79) 1 (0.85)
The data shown are for all randomized patients, unless specified.
SD: standard deviation; MDS-UPDRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale; PDQ-39: Parkinson's Disease Questionnaire-39.
a At the end of the run-in period.
b 31–90 days before the run-in period; safety analysis set (placebo, n=126; rasagiline, n= 117).
Table 2
Changes in MDS-UPDRS scores between baseline and week 26 (LOCF).
LS mean (SE) Two-sided 95% CI Difference between treatment groups (rasagiline-placebo) Two-sided 95% CI P value
MDS-UPDRS Part II + Part III
Placebo 1.87 (0.752) 0.385, 3.347 – – –
Rasagiline −4.52 (0.784) −6.068, −2.980 −6.39 −8.530, −4.250 < 0.0001
MDS-UPDRS Part III
Placebo −0.48 (0.639) −1.741, 0.775 – – –
Rasagiline −4.47 (0.666) −5.777, −3.154 −3.98 −5.800, −2.165 < 0.0001
MDS-UPDRS Part II
Placebo 2.32 (0.335) 1.661, 2.983 – – –
Rasagiline 0.13 (0.350) −0.555, 0.822 −2.19 −3.143, −1.235 < 0.0001
MDS-UPDRS Part I
Placebo 0.98 (0.247) 0.496, 1.470 – – –
Rasagiline 0.18 (0.257) −0.324, 0.687 −0.80 −1.504, −0.099 0.0255
MDS-UPDRS tremor score
Placebo 0.02 (0.223) −0.425, 0.455 – – –
Rasagiline −1.20 (0.232) −1.654, −0.741 −1.21 −1.846, −0.578 0.0002
MDS-UPDRS bradykinesia score
Placebo −0.14 (0.344) −0.819, 0.535 – – –
Rasagiline −1.69 (0.358) −2.395, −0.983 −1.55 −2.525, −0.569 0.0021
MDS-UPDRS rigidity score
Placebo −0.21 (0.166) −0.534, 0.121 – – –
Rasagiline −1.00 (0.173) −1.343, −0.660 −0.80 −1.269, −0.322 0.0011
MDS-UPDRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale; LOCF: Last Observation Carried Forward; LS: least squares; SE: standard error; CI:
confidence interval.
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Fig. 1. MDS-UPDRS Part II + Part III (A), Part III (B), Part II (C) and Part I (D) total scores change from baseline over time (Abbreviation: SD: standard deviation;
LOCF: Last Observation Carried Forward; MDS-UPDRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale).
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significant (−1.60, 95% CI: −3.586, 0.381, P=0.1128) (Table 3).
Mean changes from baseline for all individual domain scores were
numerically greater for the rasagiline group than the placebo group; the
differences between groups were statistically significant for the do-
mains activities of daily living (rasagiline-placebo: −4.68, 95% CI:
−7.950, −1.401, P=0.0053) and emotional well-being (rasagiline-
placebo: −3.70, 95% CI: −6.669, −0.724, P= 0.0150).
3.3. Safety
The proportion of patients who completed 24 weeks or more of
treatment was 79.4% in the placebo group and 93.2% in the rasagiline
group. Treatment duration was on average 157.4 (± 49.3) and 173.5
(± 31.7) days for the placebo and rasagiline groups, respectively.
The overall incidence of TEAEs was lower for the placebo group
(52.4% [66/126]) than the rasagiline group (62.4% [73/117]). Most
TEAEs in either treatment group were mild or moderate in severity; 35
patients in the placebo group (27.8%) had drug-related TEAEs, com-
pared with 46 in the rasagiline group (39.3%). TEAEs leading to dis-
continuation occurred in 8 patients in the placebo group (6.3%) and 3
patients in the rasagiline group (2.6%) (Supplementary Table 1). The
most frequent TEAE was nasopharyngitis, occurring in approximately
15% of patients in both treatment groups (Supplementary Table 2).
TEAEs related to study-drug with an incidence ≥3% in either group
were nasopharyngitis, (2.4%/4.3%, placebo/rasagiline) and eczema
(1.6%/4.3%). Serious TEAEs occurred in 8 patients in the placebo
group (6.3%) and in 4 patients in the rasagiline group (3.4%). Drug-
related serious TEAEs occurred in 5 (4.0%) and zero patients in the
placebo and rasagiline groups, respectively, while 4 (3.2%) and 1
(0.9%), respectively, discontinued from the study due to serious TEAEs.
There was one death during the study in the placebo group; the cause of
death was completed suicide; this was judged to be unlikely to be re-
lated to the study drug.
4. Discussion
To our knowledge, this was the first large randomized clinical trial
in patients with PD in Japan to utilize changes in MDS-UPDRS scores as
efficacy endpoints (instead of UPDRS scores). Although UPDRS is a
commonly used and validated scale for assessment of efficacy of PD
symptoms [20], the MDS-UPDRS is an updated and improved scale, the
results of which correlate with those of the original UPDRS, and have
been validated for the assessment of PD symptoms [16]. One of the
major changes in the revision of the UPDRS scale was the expansion of
the non-motor part in the MDS-UPDRS scale [16]. A validated Japanese
translation of the MDS-UPDRS was used in this study [17].
The primary endpoint was the change in the MDS-UPDRS Part
II + Part III total score from baseline to week 26 (LOCF). An im-
provement of −4.52 was observed in rasagiline-treated patients, com-
pared with a worsening of 1.87 in placebo-treated patients, the differ-
ence between treatments was statistically significant.
The most notable improvement with rasagiline therapy in any in-
dividual domain was with regard to the motor examination subscale
(MDS-UPDRS Part III total score), with a−4.47 point difference to the
baseline score, which, according to Horvath et al. is clinically mean-
ingful [21]. These authors found a change of −3.25 in MDS-UPDRS
Part III total score to be the minimal clinically meaningful improvement
[21]. For MDS-UPDRS Part II total score, changes of −3.05 and 2.51
were considered to be clinically meaningful improvement and wor-
sening, respectively [22]. In the present study, changes from baseline to
week 26 (LOCF) of 0.13 and 2.32 in MDS-UPDRS Part II total score were
observed for rasagiline and placebo, respectively. Therefore, the change
in the rasagiline group was not clinically meaningful, while an almost
clinically meaningful worsening was observed in the placebo group.
The changes from baseline in MDS-UPDRS Part II + Part III, Part III,
and Part II total scores at weeks 6, 10, 14, and 20 also indicated a
relative improvement with rasagiline therapy; the differences in favor
of rasagiline were maintained from week 6 until the end of the study.
In the TEMPO study in North-American patients with early PD re-
ceiving rasagiline 1mg/day as first-line treatment, there was a differ-
ence of−4.2 in the UPDRS total score, and of−2.7 in the UPDRS Part
III score, compared with placebo [11]. A meta-analysis of randomized
clinical trials in patients with early PD identified a reduction in UPDRS
total score of approximately 3 points between rasagiline and placebo
[23]. Another meta-analysis of 12 randomized trials of MAOB-Is
(mostly selegiline) in patients with early PD receiving first-line therapy
or starting treatment in the previous 12 months demonstrated a similar
benefit of −3.8 in the UPDRS motor score [24]. Most recently, an
improvement of −3.01 in the UPDRS Part II + Part III total score was
reported after 12 weeks treatment with selegiline in Japanese patients
[25]. Although the UPDRS scale was used, the symptomatic benefit
provided by rasagiline in the above studies can be considered similar to
the present study in Japanese patients, in which the MDS-UPDRS scale
was used.
Regarding the MDS-UPDRS Part I total score, in the present study
the rasagiline-placebo difference in the change from baseline to week
26 was statistically significant at−0.80. This was similar to the finding
observed in the ADAGIO study, in which a draft version of the MDS-
UPDRS Part I total was used in a secondary analysis: the change from
baseline to week 36 was 0.34 in the placebo group, and 0.01 in the
rasagiline 1mg/day group, with a −0.33 between-group difference
[26].
The change in the PDQ-39 questionnaire summary index score after
26 weeks of treatment was numerically greater in the rasagiline group
compared with placebo in the present study, but the difference was not
statistically significant. Because the present study was not powered to
detect changes in this measure, a potential reason for this lack of sig-
nificance is the relatively low PDQ-39 summary index score observed
for both treatment groups at baseline, which implies that a greater
number of patients would have been required to detect a significant
difference. Furthermore, the relative insensitivity to change of this
measure in patients with early PD has been previously suggested in
Table 3
Changes in PDQ-39 scores between baseline and week 26 (LOCF).
Placebo LS mean (SE) Rasagiline Difference between treatment groups (rasagiline-placebo) Two-sided 95% CI P value
PDQ-39 summary index 2.84 (0.699) 1.24 (0.723) −1.60 −3.586, 0.381 0.1128
Domain scores
Mobility 4.05 (1.182) 1.64 (1.222) −2.41 −5.763, 0.936 0.1571
Activities of daily living 5.66 (1.155) 0.98 (1.195) −4.68 −7.950, −1.401 0.0053
Emotional well-being 3.59 (1.044) −0.11 (1.080) −3.70 −6.669, −0.724 0.0150
Stigma 1.21 (0.980) 0.06 (1.014) −1.16 −3.946, 1.633 0.4149
Social support 2.01 (0.769) 1.11 (0.795) −0.90 −3.075, 1.282 0.4184
Cognition 2.47 (0.900) 2.14 (0.931) −0.33 −2.884, 2.222 0.7987
Communication 1.92 (0.992) 0.77 (1.026) −1.15 −3.963, 1.667 0.4225
Bodily discomfort 2.75 (1.345) 2.28 (1.391) −0.47 −4.284, 3.348 0.8093
PDQ-39: Parkinson's Disease Questionnaire-39; LOCF: Last Observation Carried Forward; LS: least squares; SE: standard error; CI: confidence interval.
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entacapone studies [27,28]. Nevertheless, for the activities of daily
living and emotional well-being sub-scores, a statistically significant
difference in the change from baseline was observed in rasagiline pa-
tients compared with placebo. Patient-reported outcomes in previous
trials have also shown to be improved following rasagiline therapy. For
example, in the TEMPO trial there were improvements from baseline to
week 26 in the PDQUALIF scale score with rasagiline 1mg/day and
2mg/day, but not with placebo [11,14]. In the PRESTO trial, a trend
towards improvement in the PDQUALIF scale score was demonstrated
for 0.5mg/day rasagiline, but not with 1mg/day rasagiline [12].
In terms of safety, the majority of TEAEs reported during treatment
with rasagiline in this study were mild, and no new safety concerns
were identified. There was a higher incidence of TEAEs in the rasagiline
group (62.4% vs. 52.4%), including those deemed to be related to the
study drug (39.3% vs. 27.8%), than in the placebo group. Serious
TEAEs, however, occurred in more patients receiving placebo (6.3%)
than in those receiving rasagiline (3.4%). Only two TEAEs had an in-
cidence of ≥5%, namely nasopharyngitis and fall, and at similar rates
between treatment groups. In the TEMPO trial, TEAEs occurred at si-
milar rates in the rasagiline and placebo groups, the overall incidence
(approximately 80%) being somewhat higher than in the current study
[11].
A potential limitation of the present study is that it was not designed
to detect the onset time of efficacy with rasagiline treatment, as the first
assessment was performed after 6 weeks of treatment, and it is possible
that efficacy could have been observed before that time. In addition,
given the chronic nature of the disease, the study was performed for a
relatively short duration of time; further studies are warranted to
evaluate the long-term efficacy of rasagiline in Japanese patients.
In conclusion, this Phase 3 study provides evidence that oral rasa-
giline 1mg/day is effective at improving symptoms of PD, including
motor symptoms, and is well tolerated in Japanese patients with early
disease. Subject to receiving official approval, rasagiline represents a
potentially valuable new treatment option as monotherapy for Japanese
patients with early PD.
Conflicts of interest
Nobutaka Hattori has served on advisory boards for Hisamitsu
Pharmaceutical Co., Inc., Sumitomo Dainippon Pharma Co. Ltd, Ono
Pharmaceutical Co. Ltd, Otsuka Pharmaceutical, Co. Ltd, Novartis
Pharma K.K., and Takeda Pharmaceuticals Co. Ltd; has performed
corporate-sponsored research for Takeda Pharmaceutical Co. Ltd; has
received honoraria from GlaxoSmithKline K.K., Nippon Boehringer
Ingelheim Co. Ltd, FP Pharmaceutical Corporation, Sumitomo
Dainippon Pharma Co. Ltd, Eisai Co. Ltd, Kissei Pharmaceutical
Company, Nihon Medi-physics Co. Ltd, Kyowa Hakko-Kirin Co. Ltd,
Novartis Pharma K.K., Biogen Japan Ltd, Acorda Therapeutics Inc.,
Otsuka Pharmaceutical Co. Ltd, Janssen Pharmaceutical K.K.,
Medtronic Japan Co. Ltd, Astellas Pharma Inc.; has received donations
from Astellas Pharma Inc., Eisai Co. Ltd, MSD K.K., Daiichi Sankyo Co.
Ltd, Novartis Pharma K.K., Takeda Pharmaceutical Co. Ltd, Nihon
Medi-physics Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, Pfizer
Japan Inc., Bayer Yakuhin Ltd, FP Pharmaceutical Corporation,
Shionogi & Co. Ltd, MSD; and has received donations for the endowed
research departments GlaxoSmithKline K.K., Nippon Boehringer
Ingelheim Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, Eisai Co. Ltd,
Kissei Pharmaceutical Co., Nihon Medi-physics Co. Ltd, Kyowa Hakko-
Kirin Co. Ltd, Medtronic Japan Co. Ltd, Novartis Pharma K.K., Ono
Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma Co., Zaiho Co.,
Asahi Kasei Medical Co. Ltd, MiZ Co. Ltd. Atsushi Takeda has served on
advisory boards for AbbVie Inc., Kyowa Hakko Kirin Co. Ltd, and
Takeda Pharmaceutical Co. Ltd; has performed corporate-sponsored
research for Hisamitsu Pharma Co. Inc., Meiji-Seika Pharma Co. Ltd,
Pfizer Japan Inc.; and has received honoraria from AbbVie Inc.,
Sumitomo Dainippon Pharma Co. Ltd, Kyowa Hakko Kirin Co. Ltd.
Shinichi Takeda, Akira Nishimura, and Tadayuki Kitagawa are em-
ployees of Takeda Pharmaceutical Co. Ltd. Hideki Mochizuki has served
on advisory boards for Hisamitsu Pharmaceutical Co. Inc., Takeda
Pharmaceutical Co. Ltd; has received honoraria from FP
Pharmaceutical Corporation, Sumitomo Dainippon Pharma Co. Ltd,
Nihon Medi-physics Co. Ltd, Kyowa Hakko-Kirin Co. Ltd, Novartis
Pharma K.K., Otsuka Pharmaceutical Co. Ltd; has received donations
from, Nihon Medi-physics Co. Ltd, Sumitomo Dainippon Pharma Co.
Ltd, Kyowa Hakko-Kirin Co. Ltd. Masahiro Nagai has served on an
advisory board for Takeda Pharmaceuticals Co. Ltd; and has received
honoraria from Novartis Pharma K.K. Ryosuke Takahashi is an em-
ployee of the Japan Agency for Medical Research and Development; has
served on advisory boards for Kan Research Institute Inc. and Sumitomo
Dainippon Pharma Co. Ltd; has performed corporate-sponsored re-
search for Novartis Pharma K.K. Co., Otsuka Pharmaceutical Co. Ltd,
Pfizer Japan Inc., Takeda Pharmaceuticals Co. Ltd, Nippon Boehringer
Ingelheim Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, Kyowa Hakko
Kirin Co. Ltd, Nihon Medi-Physics Co. Ltd, Mitsubishi Tanabe Pharma
Co. and Konica Minolta Inc.; and has received honoraria from
Sumitomo Dainippon Pharma Co Ltd and FP Pharmaceutical Co.
Funding
This study was funded by Takeda Pharmaceutical Company Limited.
Role of the funding source
The sponsor was involved in study design; in the collection, analysis
and interpretation of data; in the writing of the report; and in the de-
cision to submit the article for publication.
Author contributions
Research project
1) Conception: N. Hattori, A. Takeda, R. Takahashi, H. Mochizuki,
M. Nagai, S. Takeda, A. Nishimura.
2) Organization: H. Hattori, A. Nishimura, S. Takeda.
Statistical analysis
1) Design: T. Kitagawa, A. Nishimura.
2) Execution: T. Kitagawa.
3) Review and critique: N. Hattori, A. Takeda, R. Takahashi, H.
Mochizuki, M. Nagai, S. Takeda, A. Nishimura, T. Kitagawa.
Manuscript
1) Writing of first draft: S. Takeda, T. Kitagawa.
2) Review and critique: N. Hattori, A. Takeda, R. Takahashi, H.
Mochizuki, M. Nagai, A. Nishimura.
Acknowledgements
The authors would like to thank the patients who participated in the
clinical study and their families, as well as staff at all investigational
sites (Supplementary Table 3). The authors are also grateful to the
colleagues Masafumi Katou and Ryou Nakaya at Takeda Pharmaceu-
tical Company for reviewing the study protocol and the clinical study
report, for the development of the statistical analysis plan, and for the
statistical analysis. The authors would like to acknowledge the writing
support of Luisa Madeira, PhD, of FireKite, an Ashfield company, part of
UDG Healthcare plc, during the development of this paper, which was
funded by Takeda Pharmaceutical Company Limited, in compliance
with Good Publication Practice 3 ethical guidelines (Battisti WP et al.
Ann Intern Med 2015;163:461–4).
N. Hattori et al. Parkinsonism and Related Disorders 60 (2019) 146–152
151
Appendix A. Supplementary data
Supplementary data related to this article can be found at https://
doi.org/10.1016/j.parkreldis.2018.08.024.
References
[1] L.V. Kalia, A.E. Lang, Parkinson's disease, Lancet 386 (9996) (2015) 896–912.
[2] Alzheimer's disease facts and figures, Alzheimer's Dementia 10 (2) (2014) (2014)
e47-92.
[3] A.H. Schapira, C.W. Olanow, Drug selection and timing of initiation of treatment in
early Parkinson's disease, Ann. Neurol. 64 (Suppl 2) (2008) S47–S55.
[4] S. Tsouli, S. Konitsiotis, How should we treat a patient with early Parkinson's dis-
ease? Int. J. Clin. Pract. 64 (9) (2010) 1210–1219.
[5] A.H. Schapira, Treatment options in the modern management of Parkinson disease,
Arch. Neurol. 64 (8) (2007) 1083–1088.
[6] P. Riederer, G. Laux, MAO-inhibitors in Parkinson's disease, Exp. Neurobiol. 20 (1)
(2011) 1–17.
[7] S. Lecht, S. Haroutiunian, A. Hoffman, P. Lazarovici, Rasagiline - a novel MAO B
inhibitor in Parkinson's disease therapy, Therapeut. Clin. Risk Manag. 3 (3) (2007)
467–474.
[8] A. Takeda, [Treatment & management guidelines 2011 for Parkinson disease],
Rinsho Shinkeigaku 53 (11) (2013) 1346–1347 (Japanese).
[9] New drugs approved FY 2015. Japan Pharmaceuticals and medical devices agency
(Available at: https://www.pmda.go.jp/files/000213411.pdf Accessed on 24/
11/17.
[10] C.W. Olanow, O. Rascol, R. Hauser, P.D. Feigin, J. Jankovic, A. Lang, et al., A
double-blind, delayed-start trial of rasagiline in Parkinson's disease, N. Engl. J. Med.
361 (13) (2009) 1268–1278.
[11] Parkinson Study Group, A controlled trial of rasagiline in early Parkinson disease:
the tempo study, Arch. Neurol. 59 (12) (2002) 1937–1943.
[12] Parkinson Study Group, A randomized placebo-controlled trial of rasagiline in le-
vodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO
study, Arch. Neurol. 62 (2) (2005) 241–248.
[13] O. Rascol, D.J. Brooks, E. Melamed, W. Oertel, W. Poewe, F. Stocchi, et al.,
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor
fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given once
daily, study): a randomised, double-blind, parallel-group trial, Lancet 365 (9463)
(2005) 947–954.
[14] K.M. Biglan, S. Schwid, S. Eberly, K. Blindauer, S. Fahn, T. Goren, et al., Rasagiline
improves quality of life in patients with early Parkinson's disease, Mov. Disord. 21
(5) (2006) 616–623.
[15] T.K. Khoo, A.J. Yarnall, G.W. Duncan, S. Coleman, J.T. O'Brien, D.J. Brooks, et al.,
The spectrum of nonmotor symptoms in early Parkinson disease, Neurology 80 (3)
(2013) 276–281.
[16] C.G. Goetz, B.C. Tilley, S.R. Shaftman, G.T. Stebbins, S. Fahn, P. Martinez-Martin,
et al., Movement disorder society-sponsored revision of the unified Parkinson's
disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing re-
sults, Mov. Disord. 23 (15) (2008) 2129–2170.
[17] K. Kashihara, T. Kondo, Y. Mizuno, S. Kikuchi, S. Kuno, K. Hasegawa, et al., MDS-
UPDRS Japanese validation study group, official Japanese version of the movement
disorder society-unified Parkinson's disease rating scale: validation against the
original English version, Mov.Disord. clin. pract. 1 (3) (2014) 200–212
(Hoboken, N.J.).
[18] C.G. Goetz, W. Poewe, O. Rascol, C. Sampaio, G.T. Stebbins, C. Counsell, et al.,
Movement disorder society task force on rating scales for Parkinson's disease,
movement disorder society task force report on the Hoehn and Yahr staging scale:
status and recommendations, Mov. Disord. 19 (9) (2004) 1020–1028.
[19] C. Jenkinson, R. Fitzpatrick, V. Peto, R. Greenhall, N. Hyman, The Parkinson's
Disease Questionnaire (PDQ-39): development and validation of a Parkinson's dis-
ease summary index score, Age Ageing 26 (5) (1997) 353–357.
[20] T. Pringsheim, N. Jette, A. Frolkis, T.D.L. Steeves, The prevalence of Parkinson's
disease: a systematic review and meta-analysis, Mov. Disord. 29 (13) (2014)
1583–1590.
[21] K. Horvath, Z. Aschermann, P. Acs, G. Deli, J. Janszky, S. Komoly, E. Balazs,
K. Takacs, K. Karadi, N. Kovacs, Minimal clinically important difference on the
Motor Examination part of MDS-UPDRS, Park. Relat. Disord. 21 (12) (2015)
1421–1426.
[22] K. Horvath, Z. Aschermann, M. Kovacs, A. Makkos, M. Harmat, J. Janszky, et al.,
Minimal clinically important differences for the experiences of daily living parts of
movement disorder society-sponsored unified Parkinson's disease rating scale, Mov.
Disord. 32 (5) (2017) 789–793.
[23] S. Mínguez-Mínguez, J. Solís-García del Pozo, J. Jordán, Rasagiline in Parkinson's
disease: a review based on meta-analysis of clinical data, Pharmacol. Res. 74 (2013)
78–86.
[24] K. Turnbull, R. Caslake, A. Macleod, N. Ives, R. Stowe, C. Counsell, Monoamine
oxidase B inhibitors for early Parkinson's disease, Cochrane Database Syst. Rev. 3
(2005).
[25] Y. Mizuno, N. Hattori, T. Kondo, M. Nomoto, H. Origasa, R. Takahashi,
M. Yamamoto, N. Yanagisawa, A randomized double-blind placebo-controlled
phase III trial of selegiline monotherapy for early Parkinson disease, Clin.
Neuropharmacol. 40 (5) (2017) 201–207.
[26] W. Poewe, R.A. Hauser, A. Lang, Effects of rasagiline on the progression of non-
motor scores of the MDS-UPDRS, Mov. Disord. 30 (4) (2015) 589–592.
[27] R.A. Hauser, M. Panisset, G. Abbruzzese, L. Mancione, N. Dronamraju,
A. Kakarieka, Double-blind trial of levodopa/carbidopa/entacapone versus levo-
dopa/carbidopa in early Parkinson's disease, Mov. Disord. 24 (4) (2009) 541–550.
[28] E. Tolosa, B. Hernandez, G. Linazasoro, J.J. Lopez-Lozano, P. Mir, J. Marey, et al.,
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients
with early Parkinson's disease experiencing mild wearing-off: a randomised, double-
blind trial, J. Neural. Transm. 121 (4) (2014) 357–366.
N. Hattori et al. Parkinsonism and Related Disorders 60 (2019) 146–152
152
